Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, announces that it successfully secured £9.1 million in seed funding. The financing was co-led by Takeda Ventures, Inc.
News
AMSBIO reports upon a publication** that cites how its STEM-CELLBANKER® animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.
The Hotung Molecular Immunology group at St George’s, University of London has partnered with Leaf Expression Systems, a contract development and manufacturing organisation, specialising in plant-based expression and production of proteins, to explore the feasibility of producing anti-HIV monoclonal antibodies at large scale.
Research Triangle Park, NC, USA and Cambridge, UK, 25 May 2021 -- Inivata, a leader in liquid biopsy, today announced a collaboration with F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, for the use of Inivata’s RaDaR technology.
Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies.
Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants, announces it has raised £4.75 million in an additional financing round.
In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.
As medicines become more personalised it will become necessary to conduct phase I trials directly with the target population. This must be approached with caution and improvements to phase I to trial design must be made before transferring the well-established healthy volunteer tool kit to patients who will often have complicated medical histories.
Cambridge, UK, 20th May 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study partnership with Eli Lilly and Company (“Lilly”).